Teva Company Profile

What is the competitive landscape for TEVA

TEVA has seven hundred and thirty-eight approved drugs.

There are fifty-two US patents protecting TEVA drugs. There are fifty-five tentative approvals on TEVA drugs.

There are eight hundred and seventy-nine patent family members on TEVA drugs in forty-seven countries and one thousand one hundred and forty-six supplementary protection certificates in nineteen countries.

Summary for Teva

International Patents:	879
US Patents:	52
Tradenames:	510
Ingredients:	445
NDAs:	738
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa Inc	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	208436-001	Apr 8, 2025	AB	RX	No	No
Teva Pharms Usa	IMATINIB MESYLATE	imatinib mesylate	TABLET;ORAL	204285-002	Aug 4, 2016	AB	RX	No	No
Teva Pharms	ALENDRONATE SODIUM	alendronate sodium	TABLET;ORAL	076184-001	Feb 6, 2008		DISCN	No	No
Teva	DIVALPROEX SODIUM	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	076941-001	Jul 29, 2008		DISCN	No	No
Teva Pharms Usa	TOLTERODINE TARTRATE	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	079141-002	Nov 22, 2016	AB	RX	No	No
Teva Parenteral	ETOPOSIDE	etoposide	INJECTABLE;INJECTION	074510-001	Jun 29, 1995		DISCN	No	No
Teva Pharms Usa	TRAZODONE HYDROCHLORIDE	trazodone hydrochloride	TABLET;ORAL	071523-001	Dec 11, 1987	AB	RX	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	PROAIR RESPICLICK	albuterol sulfate	POWDER, METERED;INHALATION	205636-001	Mar 31, 2015	7,540,282
Teva Branded Pharm	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone	TABLET, CHEWABLE;ORAL	022573-001	Dec 22, 2010	5,552,394
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-003	Apr 28, 2023	8,802,127
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-003	Jan 27, 2017	6,748,947
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-002	Mar 26, 1993	4,258,062*PED
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,544,372
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017	6,748,947

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Delayed-release Tablets	20 mg		2015-06-03
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	for Injection	3.5 mg/vial		2016-10-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
Australia	2008358027
Japan	2009102408
Slovenia	2073795
Mexico	2017002551
Russian Federation	2403046
Croatia	P20150103
Hungary	E026806

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2487163	2016C/066	Belgium		PRODUCT NAME: COBICISTAT ET ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025 20150715
0582455	SPC/GB08/022	United Kingdom		PRODUCT NAME: A COMBINATION OF EFAVIRENZ, EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, AND TENOFOVIR OR A PHARMACEUTICALLY ACCEPTABLE PRODRUG, SALT OR ESTER THEREOF, PARTICULARLY TENOFOVIR DISOPROXIL, ESPECIALLY TENOFOVIR DISOPROXIL FUMARATE; REGISTERED: UK EU/1/07/430/001 20071213
1315485	132016000025193	Italy		PRODUCT NAME: LUBIPROSTONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AMITIZA); AUTHORISATION NUMBER(S) AND DATE(S): PL 21341/0003, 20120910;043833019-021, 20150526
0430190	SPC/GB05/032	United Kingdom		PRODUCT NAME: PALONOSETRON OR AN ISOMER, MIXTURE OF ISOMERS, N-OXIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/306/001 20050322
0454436	SPC/GB96/058	United Kingdom		PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0526171	SPC/GB01/047	United Kingdom		PRODUCT NAME: NATEGLINIDE; REGISTERED: CH 55401 01 20000928; CH 55401 02 20000928; UK EU/1/01/174/001 20010403; UK EU/1/01/174/002 20010403; UK EU/1/01/174/003 20010403; UK EU/1/01/174/004 20010403; UK EU/1/01/174/005 20010403; UK EU/1/01/174/006 20010403; UK EU/1/01/174/007 20010403; UK EU/1/01/174/008 20010403; UK EU/1/01/174/009 20010403; UK EU/1/01/174/010 20010403; UK EU/1/01/174/011 20010403; UK EU/1/01/174/012 20010403; UK EU/1/01/174/013 20010403; UK EU/1/01/174/014 20010403; UK EU/1/01/174/015 20010403; UK EU/1/01/174/016 20010403; UK EU/1/01/174/017 20010403; UK EU/1/01/174/018 20010403; UK EU/1/01/174/019 20010403; UK EU/1/01/174/020 20010403; UK EU/1/01/174/021 20010403
1613288	PA2011010	Lithuania		PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Inc
• Teva Pharms Intl

Pharmaceutical Competitive Landscape Analysis: Teva – Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

How does Teva position itself within the global generic and specialty pharmaceutical markets?

Teva Pharmaceutical Industries Ltd. ranks among the largest global generic drug manufacturers with a revenue of approximately $10.4 billion in 2022. Its portfolio includes over 3,500 generic medicines spanning various therapeutic areas such as analgesics, respiratory, and central nervous system (CNS) treatments. The company maintains a significant presence in North America, Europe, and emerging markets.

In 2022, Teva's market share in the U.S. generic market reached an estimated 8%, positioning it as the third-largest generic manufacturer. Its core strategy involves leveraging manufacturing scale, diversified product offerings, and cost efficiencies to compete against both generic rivals and branded pharmaceutical companies transitioning to biosimilars.

What are Teva’s key strengths in the competitive landscape?

• Manufacturing Scale and Supply Chain Verticals: Teva owns approximately net 26 manufacturing facilities globally, which facilitates high-volume production, cost control, and supply chain resilience.

• Product Diversification: With over 3,500 generic SKUs, Teva covers broad therapeutic areas, reducing revenue dependence on any single franchise.

• Biosimilar Pipeline: The company has an active biosimilars portfolio, including products such as trastuzumab and adalimumab, aligned with the industry shift toward complex biologics.

• Market Presence in the U.S.: Teva's U.S. business accounts for roughly 75% of its revenue, supported by established sales channels and regulatory approvals for key generic products.

What are the main challenges faced by Teva?

• Legal and Patent Litigation: Ongoing patent disputes and litigation expenses have led to billions in liabilities and product losses, notably for drugs like generic sildenafil and multiple branded products losing patent exclusivity.

• Pricing Pressures: Heightened competition in generic markets results in declining prices and narrower profit margins.

• Debt Burden: Post-2016 debt restructuring left Teva with more than $25 billion in debt, constraining capital allocation and strategic investments.

• Pipeline Risks: While biosimilars offer growth potential, delays in regulatory approval and market entry pose significant risks.

How does Teva’s strategic positioning compare to key competitors?

Company	Market Focus	Revenue (2022)	Core Strengths	Notable Challenges
Teva	Generics, biosimilars	$10.4B	Manufacturing scale, product breadth, biosimilar pipeline	Debt, legal liabilities, pricing pressures
Sanfofi	Branded, generics	$41.4B	Innovator pipeline, specialty drugs	Generic competition, pricing pressure
Mylan (now part of Viatris)	Generics, biosimilars	$17.7B	Cost efficiencies, global footprint	Market fragmentation, regulatory hurdles
Novartis	Branded, biosimilars	$51.6B	Innovator R&D, biosimilars	Patent cliffs, R&D costs

Teva’s focus on high-volume generics contrasts with Novartis’s emphasis on innovative branded drugs. Its biosimilar development compares favorably with Viatris, though the latter benefits from broader generic diversification.

What strategic initiatives are key to Teva’s future growth?

• Biosimilar Expansion: Investing in late-stage biosimilar development to capture biologic market share. The pipeline includes a biosimilar trastuzumab, launched in select markets.

• Portfolio Optimization: Divesting non-core assets to reduce debt and improve cash flow. Recently, Teva sold its manufacturing facilities in Italy for approximately $175 million.

• Emerging Market Penetration: Expanding presence in Latin America, Asia, and Africa to capitalize on rising healthcare access.

• Operational Efficiency: Streamlining manufacturing processes to reduce costs and improve margin stability.

What regulatory and market risk factors will shape Teva’s outlook?

• Patent Cliff Impacts: The expiry of key patents continues to erode revenues from flagship branded drugs such as Copaxone. Teva reports that generic versions of Copaxone eroded approximately $1.4 billion of its revenue over 2020–2021.

• Regulatory Delays: Biosimilar approvals face lengthy review cycles; in the U.S., regulatory agencies require extensive data packages, which prolong market entry.

• Price Controls and Reimbursement Policies: Governments, especially in Europe and North America, implement initiatives to curb drug prices, impacting profitability.

What does the competitive future landscape look like?

The generic and biosimilar space will face increased competition as market entrants leverage advanced manufacturing and AI-driven R&D. Companies like Biogen and Samsung Bioepis expand biosimilar pipelines, threatening Teva’s anticipated growth from this sector. Mergers and acquisitions in the sector aim to consolidate market share and R&D resources, potentially redefining competitive dynamics.

Key Takeaways

• Teva remains a leading generic manufacturer with strategic investments in biosimilars and emerging markets.
• The company’s debt and legal liabilities present headwinds for financial flexibility.
• Biosimilar development is central to future growth but entails regulatory and competitive risks.
• Diversification and operational efficiencies are critical to sustain profitability amid pricing pressures.
• Mergers of competitors and policy shifts in pricing present ongoing challenges and opportunities.

FAQs

1. How significant is Teva’s biosimilar pipeline?
Teva’s biosimilar pipeline includes products like trastuzumab and adalimumab, with some launched in select markets. The pipeline is considered strategic, with potential to capture sizeable biologic markets if approvals occur timely.

2. What impact did patent expirations have on Teva’s revenue?
Patent expirations, primarily for Copaxone, reduced revenue by approximately $1.4 billion in 2020–2021. Further patent cliffs are expected in the coming years, affecting financial stability.

3. How does Teva’s debt load affect its strategic options?
Post-2016 restructuring, Teva’s debt exceeds $25 billion, limiting capital expenditure, R&D investments, and acquisition activity. Debt repayment obligations also influence dividend and share repurchase policies.

4. What are the main risks for Teva in the coming years?
Key risks include delays in biosimilar approvals, intensified pricing pressures, patent cliffs, legal liabilities, and potential mergers among competitors impacting market shares.

5. Which markets are priorities for Teva’s expansion?
Emerging markets in Latin America, Southeast Asia, and Africa are targeted for expansion to offset mature market saturation and benefit from increasing healthcare spending.

---

References

1. Bloomberg. (2023). Teva Pharmaceutical Industries Ltd. Financials and market data.
2. Teva Pharmaceutical Industries Ltd. Annual Report 2022.
3. IQVIA. (2022). Global Generic Market Report.
4. FDA. (2023). Biosimilar Approval Process Overview.
5. European Medicines Agency. (2022). Biosimilar Market and Regulatory Outlook.[1][2][3][4][5]